https://www.selleckchem.com/pr....oducts/Hesperadin.ht
Aim Immune checkpoint inhibitors (ICIs) have dramatically changed the treatment paradigm in patients with non-small-cell lung cancer (NSCLC). However, progression patterns with immunotherapy are currently unclear and therapeutic options beyond resistance remain challenging. Methods We reviewed advanced NSCLC patients between January 2016 and December 2019 who were treated with anti-PD-1/PD-L1 inhibitors in our center and identified those who developed disease progression. Later-line treatment strategies were collected and objective r
Aimer
Commentaire
Partagez
Victoria Wilburn
supprimer les commentaires
Etes-vous sûr que vous voulez supprimer ce commentaire ?
Victoria Wilburn
supprimer les commentaires
Etes-vous sûr que vous voulez supprimer ce commentaire ?